Optimization of Targeted, Nanoparticle-Mediated Therapy for Enhanced Triple Negative Breast Cancer (TNBC) Treatment

Niharika Choudhury Introduction. Triple Negative Breast Cancer (TNBC) comprises 15-20% of all breast cancers and is considered the most aggressive phenotype.1,2 It is diagnosis of exclusion, characterized by the loss of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu).1,2 This genomic instability leads to…
Cancer Engineering

An Application of Lipid Nanoparticles in Delivering mRNA Vaccine for Cancer Immunotherapy

Hengji Zhang Introduction. Melanoma occurs when melanocytes in the basal layer of epidermis become cancerous. Surgical resection of the tumor and surrounding tissue is the primary treatment for localized melanoma. Before the development of targeted therapies and immunotherapies, chemotherapy was often used for patients with metastatic cancer. The BRAF inhibitors,…
Cancer Engineering

Mechanisms of Castration Resistant Prostate Cancer Progression: Intratumoral Androgen Synthesis and Overactivity of the Androgen Receptor

Gregory Wilson Introduction: Prostate cancer is the second most diagnosed cancer among males and the sixth most common cause of death of men in the world2. While first line therapies, including androgen deprivation therapy, are effective treatments for most patients, some suffer a progression of the disease to castration resistant…
Cancer

Histone Modification as an Epigenetic Mechanism Underlying Multiple Myeloma Pathogenesis

Gabriella Webster Introduction. Despite being the second most common hematologic cancer which accounts for 10% of all hematological malignancies, Multiple Myeloma is a currently incurable, genetically heterogeneous plasma cell neoplasm with a complex underlying mechanism that is poorly understood.1-3 While Multiple Myeloma is associated with specific genetic mutations and instabilities, the…
Cancer